Vibrant M&A activity expected in 2022 in both deal volume and deal value in CN market
M&A transactions and in-out-licensing in China’s life sciences market experienced a resurgence in 2021, despite distressing economic, health and social impacts caused by the global pandemic. In 2022 and beyond, investment in China’s life sciences industry will continue to benefit from the nationwide medical reform, the Chinese government’s encouragement and policy support for R&D investment, technology acquisitions, and a trend of enterprising Chinese talent returning in China in recent years. China’s biopharmaceutical market is expected to continue to attract interest and investment from global biotech giants. Technological innovations, in particular, novel market segments such as cell and gene therapy, new drugs and vaccine will remain popular acquisition/investment targets
Oncology market – Outlook for 2022: Key trends to watch
2022 appears to be heading towards being another very busy year for the oncology market, with more innovation, competitive disruption, and regulatory scrutiny.
Here the main key trends to watch:
1. Significant broadening of the checkpoint inhibitor market
2. Continued growth of radio–pharmaceuticals
3. Time in the spotlight for allogeneic therapies (in particular, natural–killer (NK)– cell directed therapies)
4. Emergence of bi–specific antibodies as competitors to CAR–T therapies
5. Growing regulatory scrutiny for oncology medicines
Healthcare M&A: Record-high valuations are forcing acquirers to get creative
Healthcare M&A volume was up 16% in 2021, and value rose by 44% after last year’s steep decline. Across the five sectors (Pharma, MedTech, payers, providers and healthcare services), deal value totaled $440 billion in 2021, with multiples at an all–time high. Companies are pursuing more cross–border deals, buying new capabilities, and continuing to acquire both carve–outs and full companies. Pharma companies purchasing to boost top–line growth and add to their portfolios and medtech companies pursuing deals that give them category leadership. Midcap pharma companies went after large acquisitions to broaden their access to new products and therapeutic areas
